A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella and Typhoid Fever

3 doses of iNTS-TCV low dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-TCV low dose Group in Stage 1 (Europe).

3 doses of iNTS-GMMA low dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-GMMA and TCV low doses Group in Stage 1 (Europe).

3 doses of TCV low dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-GMMA and TCV low doses Group in Stage 1 (Europe).

3 doses of iNTS-TCV full dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-TCV full dose\_1 Group in Stage 1 (Europe) and to participants in iNTS-TCV full dose\_2 Group in Stage 2 (Africa).

3 doses of iNTS-GMMA full dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-GMMA and TCV full doses\_1 Group in Stage 1 (Europe) and to participants in the iNTS-GMMA and TCV full doses\_2 Group in Stage 2 (Africa).

3 doses of TCV full dose vaccine administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-GMMA and TCV full doses\_1 Group in Stage 1 (Europe) and to participants in the iNTS-GMMA and TCV full doses\_2 Group in Stage 2 (Africa).

1 dose of GSK's Meningococcal A, C, Y and W-135 conjugate vaccine administered intramuscularly at Day 1 to participants in the Control\_Stage 2 Group in Stage 2 (Africa).

1 dose of GSK's Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine administered intramuscularly at Day 57 to participants in the Control\_Stage 2 Group in Stage 2 (Africa).

1 dose of Sanofi Pasteur's Typhoid Vi polysaccharide vaccine administered intramuscularly at Day 169 to participants in the Control\_Stage 2 Group in Stage 2 (Africa).

3 doses of Placebo administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the Placebo\_Step 1 and Placebo\_Step 2 in Stage 1 (Europe).

3 doses of saline solution administered intramuscularly at Day 1, Day 57, and Day 169 to participants in the iNTS-TCV low dose, Placebo\_Step 1, iNTS-TCV full dose\_1, Placebo\_Step 2 groups in Stage 1 (Europe) and to participants in iNTS-TCV full dose\_2 and Control\_Stage 2 groups in Stage 2 (Africa).